|
Wednesday 5th August 2020 |
Text too small? |
As part of the rationalisation of its distributors network, Truscreen Limited (NZX: TRU ) (“the Company”) is pleased to announce that it has appointed prominent medical device distributor Aspironix, s.r.o (Aspironix) as its exclusive distributor for Czech Republic, Slovakia, and Poland.
The territories of Czech Republic, Slovakia, and Poland, have a combined cervical cancer addressable screening population of over 17.91 million women, presenting a significant market opportunity for the Company.
Asprionix is a well-established specialised medical device distributor based in Prague, with a rapidly growing turnover and increasing presence in central and eastern Europe.
Together with Aspironix, the Company will develop a comprehensive market access plan and have begun preliminary Key Opinion Leaders (KOL) engagement for the region.
Truscreen CEO, Victoria Potarina, said “The distribution agreement with Aspironix will enable us to significantly expand our distribution capabilities in central and eastern Europe, bringing Truscreen’s latest real-time cervical cancer screening technology to the women of Czech Republic, Slovakia and Poland.
The rationalisation of our distributor portfolio will see established and committed medical device distributors, like Aspironix partnering with Truscreen to bring our Truscreen cervical cancer screening technology to the millions of women who are currently not covered by effective cervical cancer screening.”
Source: TruScreen
No comments yet
SKT - Sky ASM - Q1 Dividend Announced and Guidance Reiterated
TRA - Turners absorbs oil shock to deliver a record first half
Devon Funds Morning Note - 20 November 2026
IFT - Lodgement of Product Disclosure Statement for Capital Bond
LOD - Lodestone Energy delivers strong growth
FSF - Fonterra increases FY27 forecast Farmgate Milk Price
November 20th Morning Report
RGI - Reefton Resource Update and PFS
Devon Funds Morning Note - 19 November 2026
RYM - Ryman appoints two new directors